Koers Mabvax Therapeutics Holdings Inc Other OTC
Aandelen
US55414P7024
Biotechnologie & Medisch Onderzoek
Omzet 2016 | 148K 138K | Omzet 2017 | - | Marktkapitalisatie | 14,41 mln. 13,45 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2016 | -17 mln. -15,87 mln. | Nettowinst (verlies) 2017 | -19 mln. -17,73 mln. | EV/omzet 2016 | 147 x |
Nettoschuld 2016 | 470K 439K | Nettoschuld 2017 | 2,48 mln. 2,32 mln. | EV/omzet 2017 | - |
K/w-verhouding 2016 |
-0,93
x | K/w-verhouding 2017 |
-0,25
x | Werknemers | - |
Dividendrendement 2016 * |
-
| Dividendrendement 2017 |
-
| Vrij verhandelbaar | 92,02% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 08-07-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 08-07-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,45% | 123 mld. | |
+21,96% | 115 mld. | |
+23,73% | 25,85 mld. | |
-20,05% | 20,9 mld. | |
-16,28% | 16,77 mld. | |
-16,52% | 16,52 mld. | |
-44,35% | 15,56 mld. | |
+63,91% | 15,49 mld. | |
+2,52% | 13,45 mld. |